Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 18.72 as of 2026-09-14T23:40:14.970Z.
Consensus retrieved: 2026-09-13T22:24:10.896Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-14T23:40:14.970Z.
Quote observation: 2026-09-14T20:00:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 54bacd10f0491fd3a297ad2bd382e527969baf22037c4b97538d42d095a16556
Forward PE Ratio (18.72) = Dated Quote Price ($234.89) / Consensus Forward EPS ($12.54)
FORWARD PE RATIO
18.72
SECTOR MEDIAN · HEALTHCARE
19.44
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-3.68%
vs the sector median at left
Cardinal Health, Inc.
Market Cap
$55.01B
Forward PE Ratio
18.72
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cardinal Health, Inc. (CAH) | $55.01B | 18.72 |
| Moderna, Inc. (MRNA)vs › | $58.20B | N/A |
| Becton, Dickinson and Company (BDX)vs › | $50.40B | 14.44 |
| Edwards Lifesciences Corporation (EW)vs › | $49.24B | 28.50 |
| Humana Inc. (HUM)vs › | $48.93B | 44.51 |
| Cencora, Inc. (COR)vs › | $63.47B | 18.25 |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $45.09B | 19.48 |
| IQVIA Holdings Inc. (IQV)vs › | $43.73B | 20.49 |
| Boston Scientific Corporation (BSX)vs › | $66.96B | 13.70 |
| Agilent Technologies, Inc. (A)vs › | $41.46B | 23.67 |
Trailing P/E
32.5
reported TTM EPS
Forward P/E
18.7
consensus EPS · fiscal year ending 2027-06-30
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $12.54 implies +73.4% EPS growth vs the reported trailing $7.23.
At the dated quote price of $234.89, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-06-30 | $12.54 | $12.50 – $12.59 | 10 | 18.7x |
| 2028-06-30 | $14.09 | $13.32 – $14.34 | 10 | 16.7x |
| 2029-06-30 | $15.65 | $14.31 – $17.53 | 4 | 15.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
